Adalimumab + Methotrexate + Adalimumab placebo + Methotrexate placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Early Rheumatoid Arthritis
Conditions
Early Rheumatoid Arthritis
Trial Timeline
Dec 1, 2000 โ Apr 1, 2012
NCT ID
NCT00195663About Adalimumab + Methotrexate + Adalimumab placebo + Methotrexate placebo
Adalimumab + Methotrexate + Adalimumab placebo + Methotrexate placebo is a phase 3 stage product being developed by AbbVie for Early Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00195663. Target conditions include Early Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00195663 | Phase 3 | Completed |
Competing Products
20 competing products in Early Rheumatoid Arthritis